Table 4 Comparison of the characteristics of high-risk patients undergone different treatment
Treatment | MAB+EBRT (n=117) | MAB+EBRT+PPB (n=203) | |
Median (Range) | Median (Range) | P Value | |
Age at diagnosis (years) | 70 (59~81) | 69 (58~79) | 0.11 |
Gland volume (mL) | 32.3 (27~62) | 34.6 (29~62) | 0.09 |
Follow-up (months) | 84 (12~186) | 90 (12~186) | 0.25 |
Count (%) | Count (%) | P Value | |
Clinical stage | |||
T2b | 9 (7.7) | 14 (6.9) | 0.32 |
T2c | 63 (53.8) | 104 (51.2) | |
T3a | 28 (23.9) | 54 (26.6) | |
T3b | 17 (14.5) | 31 (15.3) | |
Gleason score | |||
≤6 | 2 (1.7) | 1 (0.5) | 0.27 |
7 | 3 (2.6) | 8 (3.9) | |
≥8 | 112 (95.7) | 194 (95.6) | |
PSA at diagnosis (ng/mL) | |||
≤10 | 17 (14.5) | 18 (8.9) | 0.13 |
10~20 | 19 (16.2) | 30 (14.8) | |
≥20 | 81 (69.2) | 155 (76.4) | |
Memorial Sloan-Kettering risk classification | |||
2~3 IS | 27 (23.1) | 44 (21.7) | 0.61 |
1 HS | 38 (32.5) | 68 (33.5) | |
2~3 HS | 52 (44.4) | 91 (44.8) | |
MAB | |||
Continuous | 58 (49.6) | 126 (62.1) | 0.07 |
Intermittent | 59 (50.4) | 77 (37.9) | |